Immune-based Therapies
Present and future of cytoreductive surgery and hyperthermic intrathoracic chemotherapy for pleural metastases: a narrative review
European Respiratory Review 2026 February 18 [Link] Amro Hajja, Miral Atout, Rasoul Turko, Haadi Syed, Paula Duarte D’Ambrosio, Ricardo Mingarini Terra, Amal Abdulhaq, Marco Nardini, Marcello Carlo Ambrogi, Marco Lucchi, Hassan Robaidi, Waleed Saleh, Khaled AlKattan, Marcello Migliore Abstract Background: Pleural malignancies pose a significant clinical challenge due to their poor prognosis and limited treatment…
Read MoreOptimising response to immunotherapies in pleural mesothelioma: clinical data and alternative models for the evaluation of new strategies
Thorax 2026 February 17 [Link] Christophe Blanquart, Arnaud Scherpereel Abstract Background: Pleural mesothelioma (PM) is a rare tumour, usually associated with previous asbestos exposure. Standard frontline, pemetrexed/platinum-based chemotherapy has been challenged since 2020 by dual immunotherapy, that is, anti-programmed cell death-1 (anti-PD-1) + anti-cytotoxic T lymphocyte-associated antigen-4 immune checkpoint inhibitors and recently by combination of…
Read MoreTreatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007-2020
Advances in Therapy 2026 March [Link] Himani Aggarwal, Ashwini Arunachalam, Jae Min, Yu-Han Kao, Haidong Feng, Danmeng Huang, Gloria Odonkor Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare malignancy typically attributed to occupational asbestos exposure and associated with dismal survival outcomes. The standard of care for unresectable MPM was platinum-based chemotherapy until the approval…
Read MorePembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial
Clinical Lung Cancer 2026 March [Link] Tetsuya Takagawa, Kanae Takahashi, Yuji Orimoto, Yukie Morisaki, Shinichiro Suna, Takashi Daimon, Takashi Kijima, Kozo Kuribayashi Abstract Background: In pleural mesothelioma (PM), platinum-based chemotherapy and immune checkpoint inhibitors including nivolumab and ipilimumab have been approved but have not shown sufficient therapeutic efficacy, and the development of new therapies is…
Read MoreComparative analysis of malignant pleural effusion and peripheral blood reveals unique T cell signatures associated with survival in mesothelioma patients
Oxford Open Immunology 2025 December 24 [Link] Nicola Principe, Kofi L P Stevens, Amber-Lee Phung, Melanie McCoy, Joel Kidman, Ali Ismail, Alistair M Cook, Abha Chopra, Mark Watson, Bruce W Robinson, Jenette Creaney, Y C Gary Lee, Jason Waithman, W Joost Lesterhuis, Richard A Lake, Anna K Nowak, Jonathan Chee, Alison M McDonnell Abstract The…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreReal-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang Abstract Background: Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However,…
Read MoreReal-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang Abstract Background: Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However,…
Read MoreDeterminants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives
Cancers 2025 December 17 [Link] Martina Delsignore, Gaia Cassinari, Simona Revello, Luigi Cerbone, Federica Grosso, Marcello Arsura, Chiara Porta Abstract Diffuse pleural mesothelioma (PM) is a rare thoracic malignancy with historically limited treatment options and poor outcomes. Despite the recent breakthrough of dual immune checkpoint blockade (ICB)-notably the combination of anti-PD-1 and anti-CTLA-4 therapies-clinical responses…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 January 9 [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition…
Read More
Skip to content